FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Golden State Medical Supply IRBESARTAN Tablets Recall

IRBESARTAN Tablets, USP 150 mg (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bot…

Golden State Medical Supply Inc. · Camarillo, CA

Risk level
Class II
Reported by FDA
Nov 28, 2018
Recall ID
D-0264-2019
Check your lot numberHow we source this data

Summary

Golden State Medical Supply recalled IRBESARTAN Tablets starting Nov 2, 2018. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0264-2019 on Nov 28, 2018. Reason: CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodiethylamine (NDEA) in product. Status: Terminated.

Why it was recalled

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodiethylamine (NDEA) in product.

Product description

IRBESARTAN Tablets, USP 150 mg (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle (NDC 60429-641-90) Rx Only, Manufactured by: SciGen Pharmaceuticals, Inc. Hauppauge, NY 11788, Distributed by: GSMS, Incorporated, Camarillo, CA 93012, USA.

Lot numbers, UPCs & expiration codes

Lot Numbers: 30-count bottles: GS019526; Exp. 11/19 GS020252; Exp. 11/19 GS020958; Exp. 11/19 Lot Numbers: 90-count bottles B161003; Exp. 09/19 B161004; Exp. 09/19 B161006; Exp. 09/19 B161007; Exp. 09/19 B161008; Exp. 11/19 B161009; Exp. 11/19 B161010; Exp. 11/19 C161001; Exp. 02/20 C161003; Exp. 05/20

Where it was sold

Product was distributed throughout the United States.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0264-2019
Classification
Class II
Status
Terminated
Recall initiated
Nov 2, 2018
FDA report date
Nov 28, 2018
Quantity
15,917 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Golden State Medical Supply Inc.

Original FDA data

Every field from FDA enforcement report D-0264-2019, exactly as published.

Show all FDA fields
City
Camarillo
State
CA
Status
Terminated
Country
United States
Event ID
81500
Address
5187 Camino Ruiz
Code information
Lot Numbers: 30-count bottles: GS019526; Exp. 11/19 GS020252; Exp. 11/19 GS020958; Exp. 11/19 Lot Numbers: 90-count bottles B161003; Exp. 09/19 B161004; Exp. 09/19 B161006; Exp. 09/19 B161007; Exp. 09/19 B161008; Exp. 11/19 B161009; Exp. 11/19 B161010; Exp. 11/19 C161001; Exp. 02/20 C161003; Exp. 05/20
Postal code
93012-8601
Report date
Nov 28, 2018
Product type
Drugs
Recall number
D-0264-2019
Classification
Class II
Recalling firm
Golden State Medical Supply Inc.
Product quantity
15,917 bottles
Termination date
Sep 16, 2020
Reason for recall
CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodiethylamine (NDEA) in product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
IRBESARTAN Tablets, USP 150 mg (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle (NDC 60429-641-90) Rx Only, Manufactured by: SciGen Pharmaceuticals, Inc. Hauppauge, NY 11788, Distributed by: GSMS, Incorporated, Camarillo, CA 93012, USA.
Distribution pattern
Product was distributed throughout the United States.
Recall initiation date
Nov 2, 2018
Initial firm notification
Letter
Center classification date
Nov 20, 2018

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0264-2019, published Nov 28, 2018. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls